Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-394-3 | CAS number: 1782069-81-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 14 March 1995 to 25 May 1995
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- Experimental information for endocrine activity discussion.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
Materials and methods
- Type of study / information:
- Thyroid function after dermal absorption
- Endpoint addressed:
- basic toxicokinetics
- dermal absorption
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- - Principle of test:
The test item was topically applied on humans in a multiple dose study to determine the effects of the test item on the thyroid.
- Short description of test conditions: Topical applications of a 6% test item or placebo water in oil emulsion was applied twice daily to human for 14 days in parallel groups. Blood samples were taken for analysis of thyroid function.
- Parameters analysed / observed: Serum samples were assayed for TBG, TSH, FT4, FT3, T4 and T3. - GLP compliance:
- yes
Test material
- Reference substance name:
- (3E)-1,7,7-trimethyl-3-(4-methylbenzylidene)bicyclo[2.2.1]heptan-2-one
- EC Number:
- 701-394-3
- Cas Number:
- 1782069-81-1
- Molecular formula:
- C18H22O
- IUPAC Name:
- (3E)-1,7,7-trimethyl-3-(4-methylbenzylidene)bicyclo[2.2.1]heptan-2-one
Constituent 1
Method
- Ethical approval:
- confirmed, but no further information available
- Details on study design:
- - Dose rationale: Approximate whole body dose of approximately 600 mg/day and the maximum allowable concentration within the EU for the test item, according to the EEC Cosmetics Directive.
- Test subjects: Healthy male and female volunteers between 18 and 40 years old (mean age: 27.8 for males, 27.7 for females). Smokers were encouraged to maintain their normal smoking habit. Subjects taking contraceptives were noted and the contraceptive method was recorded. The protocol limited the amount of paracetamol administration. All meals were standardised and controlled and alcohol was restricted completely 48 hours before the start of the test throughout the entire study period.
- Sampling: Blood samples were taken prior to the morning dose or at the corresponding time on Days 1, 4, 7, 12, 14, 16 and 21.
- Analysis: Serum samples were assayed for TSH, FT4, FT3, T4 and T3 using commercially available diagnostic kits. Thyroid volumes were calculated using Brunn's formula from ultrasound data. Blood samples were also analysed for haemotology, serum biochemistry and pregnancy (females only), and urine was analysed for drugs of abuse (alcohol, cannabinoids, amphetamines and benzodiazepines).
- Statistical methods: Repeated measures ANOVA using pre-dose day 1 values as a covariate, significance assessed at 5%. - Exposure assessment:
- measured
- Remarks:
- 91.91% of the weighed dose was applied
- Details on exposure:
- TYPE OF EXPOSURE: Dermal (600 cm2 on the dorsal surface and 600 cm2 on the ventral surface of the body). Treated skin areas were left uncovered for 4 hours after each application. Residues were wiped off with a paper towel 4 hours after the first daily dose. All participants showered for at least 5 minutes after the second daily dose.
TYPE OF EXPOSURE MEASUREMENT: Biomonitoring blood
EXPOSURE LEVELS: 6% water in oil emulsion, corresponding to 5 g test item.
EXPOSURE PERIOD: Test item was applied twice daily for 14 days. T4 has the longest serum half-life (7 days) of all the thyroid hormones assessed in this study, therefore any test item effects should be observed by Day 10 of the study at the latest.
POSTEXPOSURE PERIOD: 7 to 8 days after the last dose of the study
DESCRIPTION / DELINEATION OF EXPOSURE GROUPS / CATEGORIES: Parallel groups of humans (n = 24) were given the test item or control
Results and discussion
- Results:
- The test item was well-tolerated in the dose and application regime. The water in oil emulsion was well and rapidly absorbed and the skin was not greasy to the touch within 1 hour of application.
There were no statistically significant differences between the test item and placebo for any of the thyroid function measurements (TSH, FT4, FT3, T4, T3 and TBG). Gender, smoking and the use of hormonal contraceptives had no effect on any of the thyroid function measurements. The total thyroid volume for the test item treatment was statistically lower compared to the placebo, however post-study volumes were not statistically significant from pre-test volumes for both treatments. Thyroid volume is likely of little clinical relevance when considered together with the thyroid hormone determinations and the limitations of the accuracy of the method used.
Any other information on results incl. tables
Table 1. Summary of results
Treatment | Test item | Placebo |
Number of subjects with adverse events | 14 | 13 |
Total adverse events (a) | 18 | 18 |
Possibly related to study medication | 5 | 4 |
- Rash | 2 | 0 |
- Burning sensation on abdomen | 1 | 0 |
- Pins and needles and itching on back | 1 | 0 |
- Headache | 1 | 2 |
- Vomiting | 0 | 1 |
- Itchy macular rash | 0 | 1 |
Non-assessable | 4 | 3 |
- Dysmenorrhoea | 2 | 0 |
- Backache | 1 | 0 |
- Constipation | 1 | 0 |
- Sore throat | 0 | 2 |
- Headache | 0 | 1 |
Not related | 2 | 5 |
- Maculo-papular rash | 1 | 0 |
- Headache | 1 | 2 |
- Toothache | 0 | 1 |
- Laceration to left thigh | 0 | 1 |
- Left shoulder pain | 0 | 1 |
Remote | 7 | 6 |
- Headache | 4 | 4 |
- Itchy papular rash - left shin | 1 | 0 |
- Back pain and chest pain | 1 | 0 |
- Diarrhoea | 1 | 0 |
- Stomach ache | 0 | 1 |
- Tickle in throat | 0 | 1 |
(a) Multiple statements per subject were possible.
Applicant's summary and conclusion
- Conclusions:
- The test item was well-tolerated in the dose and application regime. There were no statistically significant differences between the test item and placebo for any of the thyroid function measurements (TSH, FT4, FT3, T4, T3 and TBG). Gender, smoking and the use of hormonal contraceptives had no effect on any of the thyroid function measurements. The total thyroid volume for the test item treatment was statistically lower compared to the placebo, however post-study volumes were not statistically significant from pre-test volumes for both treatments. Thyroid volume is likely of little clinical relevance when considered together with the thyroid hormone determinations and the limitations of the accuracy of the method used.
- Executive summary:
The test item was topically applied on humans in a multiple dose study to determine the effects of the test item on the thyroid. A 6% test item (maximum allowable concentration in the EU) or placebo water in oil emulsion was applied twice daily to healthy male and female volunteers for 14 days in parallel groups. Treatments were applied on 600 cm2 area on the dorsal surface and 600 cm2 area on the ventral surface of the body and left uncovered for 4 hours after every dose. Blood samples were taken for analysis of thyroid function (TBG, TSH, FT4, FT3, T4 and T3) on days 1, 4, 7, 12, 14, 16 and 21 and thyroid volume was estimated pre-study and post-study using ultrasound data. The test item was well-tolerated in the dose and application regime. There were no statistically significant differences between the test item and placebo for any of the thyroid function measurements (TSH, FT4, FT3, T4, T3 and TBG). Gender, smoking and the use of hormonal contraceptives had no effect on any of the thyroid function measurements. The total thyroid volume for the test item treatment was statistically lower compared to the placebo, however post-study volumes were not statistically significant from pre-test volumes for both treatments. Thyroid volume is likely of little clinical relevance when considered together with the thyroid hormone determinations and the limitations of the accuracy of the method used. This study is considered to be reliable with restriction (Klimisch 2) as it is a non-standard study, however it was well-designed and adequately reported.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.